CD40 and cancer: Previously, we demonstrated that a heterologous vaccine based on priming with peptide-pulsed dendritic cells (DCs), followed by boosting with a costimulatory agonistic CD40 antibody (Co), synthetic peptide antigen (A) and the TLR3 agonist PolyI:C (T), hereafter referred to as DC-CoAT, was able to generate massive antigen-specific CD8 T-cell responses against cancer neoepitopes within 2 weeks [7].